<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541186</url>
  </required_header>
  <id_info>
    <org_study_id>BIO89-100-221</org_study_id>
    <nct_id>NCT04541186</nct_id>
  </id_info>
  <brief_title>Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>89bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>89bio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the efficacy, safety, and tolerability of different doses&#xD;
      and dose regimens (QW or every 2 weeks [Q2W]), subcutaneous (SC) dosing of BIO89-100 compared&#xD;
      to placebo in subjects with Severe Hypertriglyceridemia (SHTG).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum TG</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage change in TG levels in subjects with SHTG (TG ≥500) mg/dL) from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achieve TG &lt;500 mg/dL</measure>
    <time_frame>Week 8</time_frame>
    <description>Proportion of subjects whose TG level is reduced to below 500 mg/dL levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very low-density lipoprotein cholesterol (VLDL-C)</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-high-density lipoprotein cholesterol (non-HDL-C)</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-density lipoprotein cholesterol (HDL-C)</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very low-density lipoprotein triglycerides (VLDL-TG)</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein B100 (ApoB)</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remnant lipoprotein cholesterol (RLP-C)</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high-sensitivity C-reactive protein (hsCRP)</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage change in metabolic markers from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting adiponectin</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage change in metabolic markers from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma body weight</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage change in metabolic markers from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum BIO89-100 concentration</measure>
    <time_frame>Week 8</time_frame>
    <description>Characterize PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal observed serum concentrations (Cmax)</measure>
    <time_frame>Week 8</time_frame>
    <description>PK parameters in Intensive PK subgroup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum drug concentration</measure>
    <time_frame>Week 8</time_frame>
    <description>PK parameters in Intensive PK subgroup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve Cmax (tmax)</measure>
    <time_frame>Week 8</time_frame>
    <description>PK parameters in Intensive PK subgroup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1⁄2)</measure>
    <time_frame>Week 8</time_frame>
    <description>PK parameters in Intensive PK subgroup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Proton Density Fat Fraction (MRI-PDFF)</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage change in hepatic steatosis from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Severe Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Main Study</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The cohort will include subjects with SHTG without concurrent fibrate therapy and will consist of 5 treatment groups to compare 4 dose levels/regimens of BIO89-100 versus placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibrate Expansion Study</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The cohort will include subjects with SHTG on stable background fibrate therapy and with a baseline MRI PDFF ≥6%, and will consist of 2 treatment groups comparing one dose regimen of BIO89 100 versus placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIO89-100</intervention_name>
    <description>BIO89-100</description>
    <arm_group_label>Fibrate Expansion Study</arm_group_label>
    <arm_group_label>Main Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Fibrate Expansion Study</arm_group_label>
    <arm_group_label>Main Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female age ≥21 to ≤75 years.&#xD;
&#xD;
          2. Screening fasting triglyceride ≥500 mg/dL and ≤2000 mg/dL.&#xD;
&#xD;
          3. Willing to follow a lifestyle for optimal control of TGs and disease management during&#xD;
             the study.&#xD;
&#xD;
          4. Patients could be taking statins and/or prescription fish oil as background therapy OR&#xD;
             not be taking any background therapy.&#xD;
&#xD;
          5. MRI-PDFF of ≥6% for subjects screened for the fibrate expansion cohort.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled or newly diagnosed hypertension.&#xD;
&#xD;
          2. Body mass index (BMI) &gt;45 kg/m2.&#xD;
&#xD;
          3. Receiving niacin, PCSK9 inhibitors, or supplements that could lower lipid levels.&#xD;
&#xD;
          4. Type 1 diabetes mellitus (T1DM).&#xD;
&#xD;
          5. Diagnosis of Type 2 diabetes mellitus (T2DM) &lt;6 months prior to screening.&#xD;
&#xD;
          6. History of malignancy within 5 years prior to screening.&#xD;
&#xD;
          7. Subjects with known lipoprotein lipase impairment or deficiency (Fredrickson Type 1),&#xD;
             apolipoprotein C-II deficiency, or familial dysbetalipoproteinemia (Fredrickson Type&#xD;
             3).&#xD;
&#xD;
          8. Clinically or otherwise documented cardiovascular or cerebrovascular disease.&#xD;
&#xD;
          9. Weight change ≥5% in 3 months prior to screening visit 1 or weight change ≥5% during&#xD;
             screening or planning to try to lose weight during conduct of study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jerome Pinkett</last_name>
    <phone>510-432-3904</phone>
    <email>Ct.gov_SHTG@89bio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Greenacres City</city>
        <state>Florida</state>
        <zip>33467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <zip>62301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Wauconda</city>
        <state>Illinois</state>
        <zip>60084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <zip>38654</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Morganton</city>
        <state>North Carolina</state>
        <zip>28655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>77365</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Lampasas</city>
        <state>Texas</state>
        <zip>76550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Magnolia</city>
        <state>Texas</state>
        <zip>77355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Prague</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Prague</city>
        <zip>150 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Prague</city>
        <zip>158 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Praha 4</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Baja</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Békéscsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Lodz</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Oswiecim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-592</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>89Bio Clinical Study Site</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89Bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertriglyceridemia</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Lipid disorder</keyword>
  <keyword>FGF21</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

